

4
2/11
60
5-23-9

52398

66

66

52398

5-23-98

5-25-78

998

998

Figure 2 SDS-PAGE of the hydrophilic fractions of *E. tenella* sporozoites used for vaccination. Stained with silver. Each set covers 3 lanes with two-fold serial dilutions of the fraction.

Figure 3 Vaccine potential of the selected antigen fractions. PBL were taken 11 days after booster vaccination and stimulated with *E. tenella* sporozoite antigen. (A) Mean proliferative PBL responses (B). Mean MAF-activity by supernatants. (C) Mean cecal lesion score of vaccinated groups following *E. tenella* challenge infection. Vertical lines indicate SEM. *Significantly different from the untreated group (* $P < 0.05$, ** $P < 0.005$, *** $P < 0.0005$).

Figure 4 Dose-effect response of antigen fraction 3. PBL were taken 11 days after booster vaccination and stimulated with *E. tenella* sporozoite antigen. (A) Mean proliferative PBL responses (B). Mean MAF-activity by supernatants. (C) Mean cecal lesion score of vaccinated groups following *E. tenella* challenge infection. Vertical lines indicate SEM. *Significantly different from the untreated group (* $P < 0.05$, ** $P < 0.005$, *** $P < 0.0005$). --

Page 4, above line 1, insert -- Detailed Description of the Invention --.

Page 32, delete lines 19 - 25 in their entirety.

Please delete page 34 in its entirety.